Presentation is loading. Please wait.

Presentation is loading. Please wait.

TITAX AMI Trial Y. Giraud-Sauveur on behalf of P.Karjalainen, MD, PhD : Principal Investigator BCIS 2009 London, UK A Prospective, Randomized Trial Comparing.

Published byKristian Phillips Modified over 9 years ago

Similar presentations

Presentation on theme: "TITAX AMI Trial Y. Giraud-Sauveur on behalf of P.Karjalainen, MD, PhD : Principal Investigator BCIS 2009 London, UK A Prospective, Randomized Trial Comparing."— Presentation transcript:

1 TITAX AMI Trial Y. Giraud-Sauveur on behalf of P.Karjalainen, MD, PhD : Principal Investigator BCIS 2009 London, UK A Prospective, Randomized Trial Comparing TITAN-2 ® Stent and TAXUS-Liberte ® Stent in Acute Myocardial Infarction 24-months Clinical Follow-Up

2 TITAX AMI trial P Karjalainen, MD, PhD Juhani Airaksinen, Antti Ylitalo, Matti Niemelä, Kari Kervinen, Mikko Pietilä, Jussi Sia, Kai Nyman, Petri Tuomainen, Timo Mäkikallio for the TITAX AMI Investigators All investigators state that no relationships exist related to this presentation

3 Titanium-NO Mechanisms of Action Inhibits Platelet Aggregation Minimizes Fibrin Growth Reduces Inflammation Promotes Healing Multifunctional Anti-restenotic Effect - Stabilizes microtubules to inhibit smooth muscle cell migration and proliferation - Stable and durable Translute Polymer * Vascular compatible, biocompatible * Controlled and consistent dose release of paclitaxel

4 Background: TITAX AMI at 1-Year Eurointerv 2008;4:234-241 TCT 2007, Late Breaking Trial Comparison of titanium-nitride-oxide-coated TITAN-2 ® Stent to the paclitaxel-eluting TAXUS-Liberte ® stent resulted in: Comparable clinical outcome at 1-Year although the overall risk of stent thrombosis was low, it concentrated on the use of TAXUS-Liberte ® stent Secondly, although the overall risk of stent thrombosis was low, it concentrated on the use of TAXUS-Liberte ® stent In addition, stent thrombosis occurred in 3 patients after premature discontinuation of clopidogrel.

5 Participating Centers in Finland Purpose of the TITAX AMI trial Initiated by the investigators A Prospective, Multi-center, Randomized Trial that Compares the Implantation of Titanium-Nitride-Oxide Coated Stents to Paclitaxel- Eluting Stents for Acute Myocardial Infarction Finland SwedenRussia * Pori * * Turku * Oulu * Kokkola * Kuopio * Jyväskylä Norway Estonia

6 Inclusion Criteria: Written informed consent Age > 18 years Patient with symptoms and signs of myocardial infarction requiring PCI Exclusion Criteria: Prior PCI on target vessel (restenosis) Unprotected LM disease Ostial lesion Contraindication to aspirin, heparins, clopidogrel, (allergy / risk for bleeding) Life expectancy < 12 months Stent length needed > 28 mm Inclusion / Exclusion

7 TITAX AMI trial: Study Design 425 Patients Presenting Acute Myocardial Infarction Requiring PCI Written Informed Consent Randomization 1:1 TITAN-2 ® stent (Hexacath) Titanium-Nitride-Oxide Coated Stent (TITANOX) 214 Patients TAXUS-Liberte ® stent (Boston) Paclitaxel-Eluting Stent (PES) 211 Patients Primary Endpoint: MACE at 1 Year Independent Endpoint Committee

8 TITAX AMI trial Primary Endpoint MACE at 12- months including Myocardial infarction TLR (PCI or CABG) Cardiac death Secondary Endpoints - Composite of cardiac death or recurrent MI - All cause death - Stent Thrombosis

9 Definition of Stent Thrombosis The Academic Research Consortium (ARC) Definite: - Acute coronary syndrome and angiographic (or autopsy) confirmation of stent thrombosis Probable: - Any unexplained death within the first 30 days - Target vessel related AMI Possible: - Any unexplained death from 30 days after PCI

10 Baseline Patient Characteristics TITAN-2 ® (N=214) TAXUS-L* ® (N=211) P value Age (mean ± SD)64 ± 11 0.72 Male sex, n (%)162 (76)157 (74)0.82 Diabetes, n (%)48 (22)33 (16)0.08 History of smoking, n (%)113 (53)97 (46)0.18 Hyperlipidemia, n (%)141 (66)151 (72)0.21 Previous PCI, n (%)22 (10)10 (5)0.04 Previous CABG, n (%)16 (7)13 (6)0.70 Acute STEMI, n (%)83 (39)97 (46)0.14 Thrombolysis, n (%)26 (12)40 (19)0.06 GP IIb/IIIa Inhibitors, n (%)116 (54)96 (45)0.81 * L= Liberte

11 Lesion Characteristics TITAN-2 ® (N=214) TAXUS-L* ® (N=211) P value Infarct-related Vessel, n (%) LAD98 (46)91 (43)0.63 LCX44 (21)50 (24)0.48 RCA62 (29)60 (28)0.92 Left Main0 (0)1 (0.5)0.50 Bypass Graft (venous)10 (5)9 (4)0.84 Complex Lesions, n (%) B1 / B2147 (69)138 (65)0.54 C35 (16)24 (11)0.16 * L= Liberte

12 Procedural and Lesion Characteristics TITAN-2 ® (N=214) TAXUS-L* ® (N=211) P Value RVD, (mm)3.16 ± 0.453.11 ± 0.500.35 Lesion length, (mm)13.6 ± 5.613.2 ± 6.40.47 Stent diameter, (mm)3.16 ± 0.423.11 ± 0.450.19 Stent length, (mm)17.4 ± 4.517.7 ± 5.30.48 Total stent length, (mm)18.5 ± 6.419.2 ± 7.20.26 No of stents per lesion, n (%)1.1 ± 0.31.1 ± 0.40.24 Acute Procedural Success, n (%)213 (99.5)207 (98.1)0.21 Multivessel PCI, n (%)30 (14)19 (9)0.13 * L= Liberte

13 Antiplatelet Agent Utilization TITAN-2 ® (N=214) TAXUS-L* ® (N=211) P value Aspirin - At 6 months 100%98.6%ns - At 12 months 100%98.6%ns Clopidogrel - At 6 months 89.3%98.1%< 0.05 - At 12 months 31.3%65.4%< 0.001 Mean duration, (months) 7.610.1< 0.001 * L= Liberte Extended clopidogrel treatments beyond 12 months were discouraged

14 Patient Flow - Clinical Randomized (N=425) TITAN-2 ® stent (N=214/214) TAXUS-Liberte ® stent (N=211/211) 1-Year follow-up (N=425/425; 100%) TITAN-2 ® stent (N=214/214) 24 months follow-up (N=424/425; 99.8%) TAXUS-Liberte ® stent (N=210/211) 1 = Lost to f/u Lost to f/u = 0

15 TITAX AMI trial MACE at 12, 18 and 24 months % p = 0.5

16 TITAX AMI trial MACE at 12, 18 and 24 months % p = 0.04 p = 0.5

17 TITAX AMI trial MACE at 12, 18 and 24 months % p = 0.04 p = 0.5 p = 0.006

18 TITAX AMI trial MI at 12, 18 and 24 months % p = 0.004 NS p < 0.001

19 TITAX AMI trial Cardiac Death at 12, 18 and 24 months % p = 0.02 NS p = 0.02

20 TITAX AMI trial TLR at 12, 18 and 24 months % NS

21 TITAX AMI trial Definite Stent Thrombosis at 12, 18 and 24 months % p = 0.003 p = 0.03 p = 0.001

22 TITAX AMI trial MI or Cardiac Death at 12, 18 and 24 months % p = 0.001 p = 0.08 p < 0.001

23 TITAX AMI trial: Conclusions (24 months follow-up) Late follow up (12 to 24 months) after the clopidogrel discontinuation showed higher rates of: - Myocardial Infarction - Cardiac Death - MACE with the use of TAXUS-Liberte ® stent Secondly, the incidence of Stent Thrombosis (ARC definition) was significantly higher in the TAXUS- Liberte ® stent group TITAN-2 ® stent: non-inferior 24-months rate of TLR

24 TITAX AMI trial Possible limitations: Small sample size (425 patients) Thrombolysis therapy not excluded Strengths of the study: Initiated by the investigators, no sponsors Prospective, randomized, multicenter study Primary clinical end point New ARC definition of stent thrombosis

25 TITAX AMI trial P Karjalainen, MD, PhD Juhani Airaksinen, Antti Ylitalo, Matti Niemelä, Kari Kervinen, Mikko Pietilä, Jussi Sia, Kai Nyman, Petri Tuomainen, Timo Mäkikallio for the TITAX AMI Investigators Thank You! Kiitos!

Download ppt "TITAX AMI Trial Y. Giraud-Sauveur on behalf of P.Karjalainen, MD, PhD : Principal Investigator BCIS 2009 London, UK A Prospective, Randomized Trial Comparing."

Similar presentations

SPIRIT IV A Prospective, Randomized Trial Comparing an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease.

SPIRIT IV A Prospective, Randomized Trial Comparing an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease.
ENDEAVOR IV Acronym: ENDEAVOR IV. Lead investigator: Dr Martin Leon from Columbia University, New York Source: Transcatheter cardiovascular Therapeutics,

ENDEAVOR IV Acronym: ENDEAVOR IV. Lead investigator: Dr Martin Leon from Columbia University, New York Source: Transcatheter cardiovascular Therapeutics,
A Prospective, Randomized Comparison of Paclitaxel-eluting TAXUS Stents vs. Bare Metal Stents During Primary Angioplasty in Acute Myocardial Infarction.

A Prospective, Randomized Comparison of Paclitaxel-eluting TAXUS Stents vs. Bare Metal Stents During Primary Angioplasty in Acute Myocardial Infarction.
Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.

Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.
Randomized Comparison of FFR-guided and Angiography-guided Provisional Stenting for True Coronary Bifurcation Lesions: The DKCRUSH-VI trial Shao-Liang.

Randomized Comparison of FFR-guided and Angiography-guided Provisional Stenting for True Coronary Bifurcation Lesions: The DKCRUSH-VI trial Shao-Liang.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,

ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
University Medical Center Groningen Thrombus aspiration during primary PCI FZ 2008-1 Thrombus Aspiration during Percutaneous coronary intervention in Acute.

University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
DIABETES trial P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín, J Goicolea, F Alfonso, C Bañuelos, J Escaned, R Moreno,

DIABETES trial P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín, J Goicolea, F Alfonso, C Bañuelos, J Escaned, R Moreno,
Clinical Result Overview

Clinical Result Overview
As presented by Patrick W. Serruys, MD, PhD, FACC Principal Investigator Thoraxcentre - Erasmus University Rotterdam, The Netherlands PISCES Paclitaxel.

As presented by Patrick W. Serruys, MD, PhD, FACC Principal Investigator Thoraxcentre - Erasmus University Rotterdam, The Netherlands PISCES Paclitaxel.
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.

SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.

CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
ARMYDA-5 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Prospective, multicenter, randomized trial investigating influence.

ARMYDA-5 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Prospective, multicenter, randomized trial investigating influence.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.

ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
HORIZONS AMI Trial H armonizing O utcomes with R evascular IZ ati ON and S tents In A cute M ycoardial I nfarction H armonizing O utcomes with R evascular.

HORIZONS AMI Trial H armonizing O utcomes with R evascular IZ ati ON and S tents In A cute M ycoardial I nfarction H armonizing O utcomes with R evascular.
Two-Year Clinical Outcomes Yan Li MD., PhD. On behalf of FIREMAN Investigators Associated Professor of Department of Cardiology of Xijing Hospital Fourth.

Two-Year Clinical Outcomes Yan Li MD., PhD. On behalf of FIREMAN Investigators Associated Professor of Department of Cardiology of Xijing Hospital Fourth.
As presented by Keith D Dawkins MD FRCP FACC Southampton University Hospital United Kingdom EuroSTAR The European Cobalt Stent with Antiproliferative for.

As presented by Keith D Dawkins MD FRCP FACC Southampton University Hospital United Kingdom EuroSTAR The European Cobalt Stent with Antiproliferative for.
Upendra Kaul, MD for the TUXEDO INDIA Investigators Paclitaxel Eluting Versus Everolimus Eluting Stents in Patients with Diabetes Mellitus and Coronary.

Upendra Kaul, MD for the TUXEDO INDIA Investigators Paclitaxel Eluting Versus Everolimus Eluting Stents in Patients with Diabetes Mellitus and Coronary.
Endeavor Safety: Pooled Analysis of Early and Late Safety of a Zotarolimus-Eluting Stent Laura Mauri, MD, MSc Brigham and Women’s Hospital Harvard Clinical.

Endeavor Safety: Pooled Analysis of Early and Late Safety of a Zotarolimus-Eluting Stent Laura Mauri, MD, MSc Brigham and Women’s Hospital Harvard Clinical.
Name of the speaker: Germano DiSciascio I have the following potential conflicts of interest to report:  Consulting  Employment in industry  Stockholder.

Name of the speaker: Germano DiSciascio I have the following potential conflicts of interest to report:  Consulting  Employment in industry  Stockholder.

Similar presentations

Ads by Google